TP53 mutations in advanced colorectal cancer: The dark side of the moon

Oncology (Switzerland)

Volumn 86, Issue 5-6, 2014, Pages 289-294

  Pietrantonio, Filippo ^a   Biondani, Pamela ^a   Perrone, Federica ^a   Di Bartolomeo, Maria ^a   Pacifici, Monica ^a   Milione, Massimo ^a   Melotti, Flavia ^a   Maggi, Claudia ^a   Montemurro, Gabriella ^a   Bossi, Ilaria ^a   Mariani, Luigi ^a   De Braud, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Biomarker; Chemotherapy; Colorectal cancer; p53; Prognosis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PROTEIN P53; UFT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; GENE SEQUENCE; PRIMARY TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902022956     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000360088     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin 2009; 59: 225-249
2. Dienstmann R, Markman B, Tabernero J: Application of monoclonal antibodies as cancer therapy in solid tumors. Curr Clin Pharmacol 2012; 7: 137-145
3. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisger DE, Housman DE, Jacks T: P53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810
4. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Pierotti MA, Miyashita T, Reed JC, Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-562
5. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF: Correlation of p53 mutations with resistance to platinum- based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984-2997
6. Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L: TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010; 28: 761-766
7. Bajetta E, Di Bartolomeo M, Buzzoni R, Mariani L, Zilembo N, Ferrario E, Lo Vullo S, Aitini E, Isa L, Barone C, Jacobelli S, Recaldin E, Pinotti G, Iop A: Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: Results of a randomised phase II study. Br J Cancer 2007; 96: 439-444
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
9. Di Bartolomeo M, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E: Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Target Oncol 2013, Epub ahead of print
10. Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantu G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S: Highrisk human papilloma virus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-5636
11. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23: 3328-3337
12. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424-8429
13. Pietrantonio F, Biondani P, De Braud F, Pellegrinelli A, Bianchini G, Perrone F, Formisano B, Di Bartolomeo M: BAX expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. Transl Oncol 2012; 5: 155-159
14. Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56: 892-898
15. McDermott U, Longley D, Gallian L, Allen LW, Wilson T, Johnston PG: Effect of P53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res 2005; 65: 8951-8960
16. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
17. Munro AJ, Lain S, Lane DP: P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 2005; 92: 434-444
18. Westra JL, Schaapveld M, Hollema H, De Boer JP, Kraak M, De Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT: Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant- treated stage III colon cancer patients. J Clin Oncol 2005; 23: 5635-5643
19. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B: P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001; 7: 1343-1349
20. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC: P53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996; 69: 190-192
21. De Bruijn MT, Raats DA, Tol J, Hinrichs J, Teerenstra S, Punt CJ, Rinkes IH, Kranenburg O: Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. Anticancer Res 2011; 31: 1379-1385
22. Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissiere F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P, Frebourg T: TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab- based chemotherapy. Br J Cancer 2009; 100: 1330-1335.